Methods and compositions of neuregulins for preventing, treating or delaying preserved ejection fraction cardiac failure

Abstract

Disclosed are the use of neuregulin proteins in preparing a medicine for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, and a method for using the medicine. Also provided in the present invention is a method for preventing, treating or delaying preserved ejection fraction cardiac failure in mammals, comprising using the medication containing the neuregulin proteins in a special population having the disease or being at risk of having the disease.

1 - 4 . (canceled) 
     
     
         5 . A pharmaceutical preparation for, treating heart failure with preserved ejection fraction in a mammal, which comprises an effective amount of neuregulin. 
     
     
         6 . The pharmaceutical preparation of  claim 5 , wherein the neuregulin is NRG-1. 
     
     
         7 . The pharmaceutical preparation of  claim 5 , wherein the neuregulin comprises the amino acid sequence of SEQ ID NO: 1. 
     
     
         8 . The pharmaceutical preparation of  claim 5 , wherein the mammal is human. 
     
     
         9 . A composition for, treating heart failure with preserved ejection fraction in a mammal, which comprises a pharmaceutical preparation and one or more other drugs for treating heart failure with preserved ejection fraction, wherein the pharmaceutical preparation comprises an effective amount of neuregulin. 
     
     
         10 . A kit used for, treating heart failure with preserved ejection fraction in a mammal, which comprises one or more doses of a pharmaceutical preparation and instructions on how to use the pharmaceutical preparation, wherein the pharmaceutical preparation comprises neuregulin. 
     
     
         11 . The pharmaceutical preparation of  claim 5 , wherein the pharmaceutical preparation is in a dosage form of lyophilized powder. 
     
     
         12 . The pharmaceutical preparation of  claim 5 , wherein the pharmaceutical preparation is in a dosage form for intravenous injection. 
     
     
         13 . The composition of  claim 9 , wherein the one or more other drugs comprise angiotensin converting enzyme inhibitors, angiotensin II receptor inhibitors, beta receptor antagonists, calcium antagonists, cyclic adenosine monophosphate, catecholamines, nitrates phosphatase inhibitors, diuretics, renin angiotensin aldosterone system (RAS) antagonists, or myocardial energy optimization agents. 
     
     
         14 . The composition of  claim 9 , wherein the one or more other drugs comprise an angiotensin converting enzyme inhibitor. 
     
     
         15 . The composition of  claim 14 , wherein the angiotensin converting enzyme inhibitor is captopril. 
     
     
         16 . The kit of  claim 10 , wherein each of the one or more doses of the pharmaceutical preparation comprises recombinant human neuregulin at an amount of 0.3 μg/kg/day.